Statute Details
- Title: Medicines (Veterinary Medicinal Products) (Import and Product Licences) Regulations
- Act Code: MA1975-RG1
- Type: Subsidiary legislation (sl)
- Authorising Act: Medicines Act (Chapter 176), Section 74
- Commencement Date: Not stated in the provided extract
- Current version status: Current version as at 27 Mar 2026 (per the platform display)
- Key subject matter: Licensing regime for veterinary medicinal products—product licences and import licences; ongoing duties for licence holders and importers
- Key provisions (from extract): Regulations 3–14 (including validity periods, application requirements, post-licence obligations, record-keeping, substandard product controls, fees, and penalties)
What Is This Legislation About?
The Medicines (Veterinary Medicinal Products) (Import and Product Licences) Regulations (“the Regulations”) create a regulatory framework in Singapore for veterinary medicinal products. In practical terms, they control (i) when and how veterinary medicinal products can be imported into Singapore and (ii) when a veterinary medicinal product can be placed on the market through a product licensing system.
The Regulations sit under the Medicines Act (Chapter 176) and are designed to protect public health, animal health, and broader safety concerns (including risks to livestock and wildlife). They do this by requiring applicants to provide scientific and safety information, by imposing duties on licence holders to update the licensing authority when relevant information changes, and by requiring importers to maintain records that allow regulatory oversight.
Although the Regulations are technical, their legal effect is straightforward: they establish licensing conditions and compliance obligations, and they provide enforcement tools (including directions to withhold substandard products and criminal penalties for non-compliance). For practitioners, the most important features are the validity periods, the scope of application and supporting data, the “forthwith” notification duties after licensing, and the record-keeping and substandard-product provisions.
What Are the Key Provisions?
1) Validity of product licences and provisional licences (Regulation 3)
A product licence (other than a provisional product licence) is granted for 5 years, or for any shorter period the licensing authority may determine. A provisional product licence is granted for 2 years, or for any shorter period the licensing authority may determine. This structure indicates that the licensing authority may use provisional approvals where full data or final assessment is not yet complete, while still requiring regulatory oversight.
2) Validity and scope of import licences (Regulation 4)
Every import licence is valid only for one consignment of veterinary medicinal products for which the application was made. The licence is in force for one month from the date of issue. This is a significant operational constraint: importers must align applications and logistics with the licence’s short validity and consignment-specific nature. It also reduces the risk of “stockpiling” under a single approval.
3) Application requirements for product licences and provisional product licences (Regulations 5 and 6)
Applications must be made to the licensing authority in the required form and manner and must be accompanied by whatever information, documents, samples, and other material the authority requires. Critically, the Regulations require a separate application for each veterinary medicinal product (Regulation 5(2)).
There is, however, an important consolidation rule: a single application may cover 2 or more veterinary medicinal products if they share the same pharmaceutical form and consist of either (a) a single active constituent in different strengths, or (b) a mixture of two or more active constituents in different strengths but in the same proportion (Regulation 5(3)). This is legally relevant for portfolio management and for how applicants structure submissions.
Regulation 6 sets out the categories of particulars that must be submitted. These include: (a) chemical, pharmaceutical, experimental, and biological studies; (b) animal tests and studies; (c) possible hazards to man, livestock, and wildlife; and (d) precautions or contra-indications. For counsel advising applicants, this provision is a roadmap for what the licensing authority will expect to see in the dossier and how safety and efficacy evidence must be framed.
4) Post-licence duties: changes, new information, adverse effects, and withdrawal (Regulations 7–10)
Once a product licence (or provisional product licence) is granted, the holder must comply with ongoing disclosure obligations.
Regulation 7 (Changes in particulars): The holder must forthwith inform the licensing authority of any material change made or proposed in the application particulars. The change must relate to: (a) the product specification; (b) constituent specifications; (c) composition; or (d) methods and procedures ensuring compliance with product specifications. The “forthwith” standard is strict and is likely to be interpreted as prompt notification without undue delay.
Regulation 8 (Further information): The holder must also forthwith inform the licensing authority of any information received that casts doubt on the continued validity of data submitted for assessing safety, quality, or efficacy. This is a legal trigger for reassessment: even if the holder has not changed the product, new evidence undermining the original data must be disclosed.
Regulation 9 (Adverse effects): The holder must inform the licensing authority of any reports of adverse effects on human beings or animals (or both) associated with the use of the veterinary medicinal product or its constituents. The licensing authority may require the holder to furnish copies of such reports. This provision creates a pharmacovigilance-like obligation tailored to veterinary products.
Regulation 10 (Withdrawal from sale, supply, or exportation): If the holder decides to withdraw a product from sale, supply, or exportation, it must notify the licensing authority forthwith and state the reason. This ensures that regulatory authorities can manage market and safety risks quickly.
5) Importer record-keeping and inspection (Regulation 11)
Regulation 11 imposes a record-keeping duty on importers. Importers must keep records of their imports and distribution of veterinary medicinal products readily available for inspection by the licensing authority. If directed, the importer must submit the records.
The records must not be destroyed for 5 years from the date of importation. The Regulations also require that records be kept in a way that facilitates withholding from sale, supply, or exportation of veterinary medicinal products. This is a compliance and traceability requirement: it supports rapid regulatory action if a product is found to be substandard.
6) Substandard veterinary medicinal products: regulatory directions (Regulation 12)
Where a veterinary medicinal product is suspected or found not to conform regarding strength, quality, or purity with the product specification or with the Medicines Act or regulations, the licensing authority may direct the importer or any person in possession of the product to withhold it from sale, supply, or exportation for a period specified by the authority. This is a powerful intervention mechanism. It does not require a final determination in court; it can be triggered by suspicion as well as confirmed non-conformity.
7) Fees and penalties (Regulations 13 and 14)
Fees are set as follows: $3 per consignment for an import licence; $50 per product for a product licence; and $25 per product for a provisional product licence (Regulation 13). These fees are relatively modest but are still legally relevant for budgeting and for structuring applications.
Enforcement is addressed in Regulation 14. Any person who contravenes or fails to comply with Regulations 7, 8, 9, 10, or 11, or fails to comply with any direction under Regulation 12, commits an offence. On conviction, the person is liable to a fine not exceeding $2,000. For practitioners, the key point is that the penalty provision ties directly to the most operationally important compliance duties: change notifications, new information, adverse effects reporting, withdrawal notifications, record-keeping, and compliance with withholding directions.
How Is This Legislation Structured?
The Regulations are structured as a sequence of licensing and compliance rules, moving from definitions and licence validity to application mechanics, then to ongoing duties and enforcement. The key flow is:
(1) Citation and definitions (Regulations 1–2).
(2) Licence validity (Regulations 3–4).
(3) Application and submission requirements (Regulations 5–6).
(4) Ongoing disclosure and information duties (Regulations 7–10).
(5) Record-keeping and regulatory controls (Regulations 11–12).
(6) Fees and penalties (Regulations 13–14).
Who Does This Legislation Apply To?
The Regulations apply primarily to product licence holders (including holders of provisional product licences) and to importers of veterinary medicinal products. Regulation 2 defines “importer” as an importer of veterinary medicinal products, and Regulation 11 places record-keeping obligations specifically on importers.
In addition, Regulation 12 extends the authority’s reach beyond the importer: where a product is suspected or found substandard, the licensing authority may direct the importer or any person in possession of the product to withhold it from sale, supply, or exportation. This means compliance planning should consider not only the corporate importer but also downstream handlers who may hold stock in Singapore.
Why Is This Legislation Important?
For legal and regulatory practitioners, these Regulations are important because they operationalise the Medicines Act’s licensing policy for veterinary medicinal products. They create a legally enforceable framework that governs both entry into the market (product licensing) and entry into Singapore (import licensing), while also requiring continuous compliance after approval.
From a risk-management perspective, the most consequential provisions are the “forthwith” notification duties (Regulations 7–10) and the record-keeping and traceability requirements (Regulation 11). These provisions are designed to ensure that regulatory authorities can respond quickly to safety concerns, data invalidation, adverse effects, and withdrawal decisions. They also support enforcement actions if a product is found to be substandard.
Practically, counsel advising applicants and licence holders should treat the Regulations as a compliance checklist: (i) structure applications correctly (including the “single application” consolidation rule); (ii) maintain robust evidence for safety, quality, and efficacy; (iii) implement internal processes to detect and report material changes and new information promptly; (iv) establish pharmacovigilance workflows for adverse effects; (v) maintain import and distribution records for at least five years; and (vi) be prepared to comply with withholding directions under Regulation 12.
Related Legislation
- Medicines Act (Chapter 176), in particular Section 74 (authorising the making of these Regulations)
Source Documents
This article provides an overview of the Medicines (Veterinary Medicinal Products) (Import and Product Licences) Regulations for legal research and educational purposes. It does not constitute legal advice. Readers should consult the official text for authoritative provisions.